Cancer Vaccines Market By Vaccine Type (Prophylactic Vaccines {Human Papillomavirus (HPV) Vaccines, Hepatitis B Virus (HBV) Vaccines} Therapeutic Vaccines {Recombinant Cancer Vaccines, Oncolytic Virus-Based Vaccines, Personalized Cancer Vaccines, Others}), By Cancer Type (Cervical Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Bladder Cancer, Others), By Technology (Peptide Vaccines {Long Peptides, Short Peptides}, Dendritic Cell Vaccines, Tumor Cell Vaccines {Autologous Tumor Vaccines, Allogeneic Tumor Vaccines}, Viral Vector & DNA Vaccines {Adenovirus-based Vaccines, Lentivirus-based Vaccines, mRNA-based Vaccines}), By Route of Administration (Intradermal, Intravenous, Intramuscular), and By End-user (Hospitals & Clinics, Cancer Treatment Centers, Research Institutes & Academic Centers, Specialty Cancer Clinics), Global Market Size, Segmental analysis, Regional Overview, Company Share Analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Cancer Vaccines Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Rising cancer rates globally drive demand for effective prevention and treatment options.

3.2.2. Innovations in vaccine technology, such as mRNA and viral vector platforms, enhance efficacy.

3.2.3. Increased public awareness about cancer prevention and the benefits of vaccination.

3.3. Key industry pitfalls & challenges

3.3.1. Concerns about potential side effects can deter patients from opting for vaccination.

3.3.2. Navigating complex regulatory pathways can delay product launches.

3.3.3. Economic instability can lead to reduced healthcare spending, impacting vaccine investments.

3.4. Market Opportunities

3.4.1. Developing personalized cancer vaccines tailored to individual patient profiles.

3.4.2. Integrating cancer vaccines with gene therapy approaches to boost efficacy.

3.4.3. Collaborating with research institutions and biotech firms to innovate.

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Cancer Vaccines Market, Vaccine Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Vaccine Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Prophylactic Vaccines

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.2. Human Papillomavirus (HPV) Vaccines

4.2.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.3. Hepatitis B Virus (HBV) Vaccines

4.2.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.4. Others

4.2.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Therapeutic Vaccines

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.2. Recombinant Cancer Vaccines

4.3.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.3. Oncolytic Virus-Based Vaccines

4.3.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.4. Personalized Cancer Vaccines

4.3.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.5. Others

4.3.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Cancer Vaccines Market, Cancer Type Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Cancer Type, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Cervical Cancer

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Prostate Cancer

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Lung Cancer:

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Colorectal Cancer

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.6. Breast Cancer

5.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.7. Bladder Cancer

5.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.8. Others

5.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Cancer Vaccines Market, Technology Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Technology, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Peptide Vaccines

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.2.2. Long Peptides

6.2.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.2.3. Short Peptides

6.2.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Dendritic Cell Vaccines

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Tumor Cell Vaccines

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4.2. Autologous Tumor Vaccines

6.4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4.3. Allogeneic Tumor Vaccines

6.4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Viral Vector & DNA Vaccines

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5.2. Adenovirus-based Vaccines

6.5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5.3. Lentivirus-based Vaccines

6.5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5.4. mRNA-based Vaccines

6.5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Cancer Vaccines Market, Distribution Channel Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By Distribution Channel, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Intradermal

7.2.1.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Intravenous

7.3.1.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Intramuscular

7.4.1.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Cancer Vaccines Market, End-user Segment Analysis

8.1. Overview

8.1.1. Market Revenue Share, By End-user, 2025 & 2035

8.1.2. Key Market Trends, Growth Factors, & Opportunities

8.2. Hospitals & Clinics

8.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.3. Cancer Treatment Centers

8.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.4. Research Institutes & Academic Centers

8.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.5. Specialty Cancer Clinics

8.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

9. Cancer Vaccines Market, Region Segment Analysis

9.1. Overview

9.1.1. Global Market Revenue Share, By Region, 2025 & 2035

9.1.2. Global Market Revenue, By Region, 2025-2035 (USD Billion)

9.2. North America

9.2.1. North America Market Revenue, By Country, 2025-2035 (USD Billion)

9.2.2. North America Market Revenue, By Vaccine Type, 2025-2035

9.2.3. North America Market Revenue, By Cancer Type, 2025-2035

9.2.4. North America Market Revenue, By Technology, 2025-2035

9.2.5. North America Market Revenue, By Distribution Channel, 2025-2035

9.2.6. North America Market Revenue, By End-user, 2025-2035

9.2.7. The U.S.

9.2.7.1. U.S. Market Revenue, By Vaccine Type, 2025-2035

9.2.7.2. U.S. Market Revenue, By Cancer Type, 2025-2035

9.2.7.3. U.S. Market Revenue, By Technology, 2025-2035

9.2.7.4. U.S. Market Revenue, By Distribution Channel, 2025-2035

9.2.7.5. U.S. Market Revenue, By End-user, 2025-2035

9.2.8. Canada

9.2.8.1. Canada Market Revenue, By Vaccine Type, 2025-2035

9.2.8.2. Canada Market Revenue, By Cancer Type, 2025-2035

9.2.8.3. Canada Market Revenue, By Technology, 2025-2035

9.2.8.4. Canada Market Revenue, By Distribution Channel, 2025-2035

9.2.8.5. Canada Market Revenue, By End-user, 2025-2035

9.3. Europe

9.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Billion)

9.3.2. Europe Market Revenue, By Vaccine Type, 2025-2035

9.3.3. Europe Market Revenue, By Cancer Type, 2025-2035

9.3.4. Europe Market Revenue, By Technology, 2025-2035

9.3.5. Europe Market Revenue, By Distribution Channel, 2025-2035

9.3.6. Europe Market Revenue, By End-user, 2025-2035

9.3.7. Germany

9.3.7.1. Germany Market Revenue, By Vaccine Type, 2025-2035

9.3.7.2. Germany Market Revenue, By Cancer Type, 2025-2035

9.3.7.3. Germany Market Revenue, By Technology, 2025-2035

9.3.7.4. Germany Market Revenue, By Distribution Channel, 2025-2035

9.3.7.5. Germany Market Revenue, By End-user, 2025-2035

9.3.8. France

9.3.8.1. France Market Revenue, By Vaccine Type, 2025-2035

9.3.8.2. France Market Revenue, By Cancer Type, 2025-2035

9.3.8.3. France Market Revenue, By Technology, 2025-2035

9.3.8.4. France Market Revenue, By Distribution Channel, 2025-2035

9.3.8.5. France Market Revenue, By End-user, 2025-2035

9.3.9. U.K.

9.3.9.1. U.K. Market Revenue, By Vaccine Type, 2025-2035

9.3.9.2. U.K. Market Revenue, By Cancer Type, 2025-2035

9.3.9.3. U.K. Market Revenue, By Technology, 2025-2035

9.3.9.4. U.K. Market Revenue, By Distribution Channel, 2025-2035

9.3.9.5. U.K. Market Revenue, By End-user, 2025-2035

9.3.10. Italy

9.3.10.1. Italy Market Revenue, By Vaccine Type, 2025-2035

9.3.10.2. Italy Market Revenue, By Cancer Type, 2025-2035

9.3.10.3. Italy Market Revenue, By Technology, 2025-2035

9.3.10.4. Italy Market Revenue, By Distribution Channel, 2025-2035

9.3.10.5. Italy Market Revenue, By End-user, 2025-2035

9.3.11. Spain

9.3.11.1. Spain Market Revenue, By Vaccine Type, 2025-2035

9.3.11.2. Spain Market Revenue, By Cancer Type, 2025-2035

9.3.11.3. Spain Market Revenue, By Technology, 2025-2035

9.3.11.4. Spain Market Revenue, By Distribution Channel, 2025-2035

9.3.11.5. Spain Market Revenue, By End-user, 2025-2035

9.3.12. Rest of Europe

9.3.12.1. Rest of Europe Market Revenue, By Vaccine Type, 2025-2035

9.3.12.2. Rest of Europe Market Revenue, By Cancer Type, 2025-2035

9.3.12.3. Rest of Europe Market Revenue, By Technology, 2025-2035

9.3.12.4. Rest of Europe Market Revenue, By Distribution Channel, 2025-2035

9.3.12.5. Rest of Europe Market Revenue, By End-user, 2025-2035

9.4. Asia Pacific

9.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Billion)

9.4.2. Asia Pacific Market Revenue, By Vaccine Type, 2025-2035

9.4.3. Asia Pacific Market Revenue, By Cancer Type, 2025-2035

9.4.4. Asia Pacific Market Revenue, By Technology, 2025-2035

9.4.5. Asia Pacific Market Revenue, By Distribution Channel, 2025-2035

9.4.6. Asia Pacific Market Revenue, By End-user, 2025-2035

9.4.7. China

9.4.7.1. China Market Revenue, By Vaccine Type, 2025-2035

9.4.7.2. China Market Revenue, By Cancer Type, 2025-2035

9.4.7.3. China Market Revenue, By Technology, 2025-2035

9.4.7.4. China Market Revenue, By Distribution Channel, 2025-2035

9.4.7.5. China Market Revenue, By End-user, 2025-2035

9.4.8. Japan

9.4.8.1. Japan Market Revenue, By Vaccine Type, 2025-2035

9.4.8.2. Japan Market Revenue, By Cancer Type, 2025-2035

9.4.8.3. Japan Market Revenue, By Technology, 2025-2035

9.4.8.4. Japan Market Revenue, By Distribution Channel, 2025-2035

9.4.8.5. Japan Market Revenue, By End-user, 2025-2035

9.4.9. India

9.4.9.1. India Market Revenue, By Vaccine Type, 2025-2035

9.4.9.2. India Market Revenue, By Cancer Type, 2025-2035

9.4.9.3. India Market Revenue, By Technology, 2025-2035

9.4.9.4. India Market Revenue, By Distribution Channel, 2025-2035

9.4.9.5. India Market Revenue, By End-user, 2025-2035

9.4.10. Australia

9.4.10.1. Australia Market Revenue, By Vaccine Type, 2025-2035

9.4.10.2. Australia Market Revenue, By Cancer Type, 2025-2035

9.4.10.3. Australia Market Revenue, By Technology, 2025-2035

9.4.10.4. Australia Market Revenue, By Distribution Channel, 2025-2035

9.4.10.5. Australia Market Revenue, By End-user, 2025-2035

9.4.11. South Korea

9.4.11.1. South Korea Market Revenue, By Vaccine Type, 2025-2035

9.4.11.2. South Korea Market Revenue, By Cancer Type, 2025-2035

9.4.11.3. South Korea Market Revenue, By Technology, 2025-2035

9.4.11.4. South Korea Market Revenue, By Distribution Channel, 2025-2035

9.4.11.5. South Korea Market Revenue, By End-user, 2025-2035

9.4.12. Singapore

9.4.12.1. Singapore Market Revenue, By Vaccine Type, 2025-2035

9.4.12.2. Singapore Market Revenue, By Cancer Type, 2025-2035

9.4.12.3. Singapore Market Revenue, By Technology, 2025-2035

9.4.12.4. Singapore Market Revenue, By Distribution Channel, 2025-2035

9.4.12.5. Singapore Market Revenue, By End-user, 2025-2035

9.4.13. Rest of Asia Pacific

9.4.13.1. Rest of Asia Pacific Market Revenue, By Vaccine Type, 2025-2035

9.4.13.2. Rest of Asia Pacific Market Revenue, By Cancer Type, 2025-2035

9.4.13.3. Rest of Asia Pacific Market Revenue, By Technology, 2025-2035

9.4.13.4. Rest of Asia Pacific Market Revenue, By Distribution Channel, 2025-2035

9.4.13.5. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035

9.5. Latin America

9.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Billion)

9.5.2. Latin America Market Revenue, By Vaccine Type, 2025-2035

9.5.3. Latin America Market Revenue, By Cancer Type, 2025-2035

9.5.4. Latin America Market Revenue, By Technology, 2025-2035

9.5.5. Latin America Market Revenue, By Distribution Channel, 2025-2035

9.5.6. Latin America Market Revenue, By End-user, 2025-2035

9.5.7. Brazil

9.5.7.1. Brazil Market Revenue, By Vaccine Type, 2025-2035

9.5.7.2. Brazil Market Revenue, By Cancer Type, 2025-2035

9.5.7.3. Brazil Market Revenue, By Technology, 2025-2035

9.5.7.4. Brazil Market Revenue, By Distribution Channel, 2025-2035

9.5.7.5. Brazil Market Revenue, By End-user, 2025-2035

9.5.8. Argentina

9.5.8.1. Argentina Market Revenue, By Vaccine Type, 2025-2035

9.5.8.2. Argentina Market Revenue, By Cancer Type, 2025-2035

9.5.8.3. Argentina Market Revenue, By Technology, 2025-2035

9.5.8.4. Argentina Market Revenue, By Distribution Channel, 2025-2035

9.5.8.5. Argentina Market Revenue, By End-user, 2025-2035

9.5.9. Mexico

9.5.9.1. Mexico Market Revenue, By Vaccine Type, 2025-2035

9.5.9.2. Mexico Market Revenue, By Cancer Type, 2025-2035

9.5.9.3. Mexico Market Revenue, By Technology, 2025-2035

9.5.9.4. Mexico Market Revenue, By Distribution Channel, 2025-2035

9.5.9.5. Mexico Market Revenue, By End-user, 2025-2035

9.5.10. Rest of Latin America

9.5.10.1. Rest of Latin America Market Revenue, By Vaccine Type, 2025-2035

9.5.10.2. Rest of Latin America Revenue, By Cancer Type, 2025-2035

9.5.10.3. Rest of Latin America Market Revenue, By Technology, 2025-2035

9.5.10.4. Rest of Latin America Market Revenue, By Distribution Channel, 2025-2035

9.5.10.5. Rest of Latin America Market Revenue, By End-user, 2025-2035

9.6. MEA

9.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Billion)

9.6.2. MEA Market Revenue, By Vaccine Type, 2025-2035

9.6.3. MEA Market Revenue, By Cancer Type, 2025-2035

9.6.4. MEA Market Revenue, By Technology, 2025-2035

9.6.5. MEA Market Revenue, By Distribution Channel, 2025-2035

9.6.6. MEA Market Revenue, By End-user, 2025-2035

9.6.7. GCC Countries

9.6.7.1. GCC Countries Market Revenue, By Vaccine Type, 2025-2035

9.6.7.2. GCC Countries Market Revenue, By Cancer Type, 2025-2035

9.6.7.3. GCC Countries Market Revenue, By Technology, 2025-2035

9.6.7.4. GCC Countries Market Revenue, By Distribution Channel, 2025-2035

9.6.7.5. GCC Countries Market Revenue, By End-user, 2025-2035

9.6.8. South Africa

9.6.8.1. South Africa Market Revenue, By Vaccine Type, 2025-2035

9.6.8.2. South Africa Market Revenue, By Cancer Type, 2025-2035

9.6.8.3. South Africa Market Revenue, By Technology, 2025-2035

9.6.8.4. South Africa Market Revenue, By Distribution Channel, 2025-2035

9.6.8.5. South Africa Market Revenue, By End-user, 2025-2035

9.6.9. Rest of Middle-East & Africa

9.6.9.1. Rest of Middle-East & Africa Market Revenue, By Vaccine Type, 2025-2035

9.6.9.2. Rest of Middle-East & Africa Market Revenue, By Cancer Type, 2025-2035

9.6.9.3. Rest of Middle-East & Africa Market Revenue, By Technology, 2025-2035

9.6.9.4. Rest of Middle-East & Africa Market Revenue, By Distribution Channel, 2025-2035

9.6.9.5. Rest of Middle-East & Africa Market Revenue, By End-user, 2025-2035

10. Company Profile

10.1. Merck & Co.

10.1.1. Business Overview

10.1.2. Financial Performance

10.1.3. Product/Service Offerings

10.1.4. Strategies & recent developments

10.1.5. SWOT Analysis

10.2. Bristol-Myers Squibb

10.2.1. Business Overview

10.2.2. Financial Performance

10.2.3. Product/Service Offerings

10.2.4. Strategies & recent developments

10.2.5. SWOT Analysis

10.3. Roche

10.3.1. Business Overview

10.3.2. Financial Performance

10.3.3. Product/Service Offerings

10.3.4. Strategies & recent developments

10.3.5. SWOT Analysis

10.4. Moderna

10.4.1. Business Overview

10.4.2. Financial Performance

10.4.3. Product/Service Offerings

10.4.4. Strategies & recent developments

10.4.5. SWOT Analysis

10.5. BioNTech

10.5.1. Business Overview

10.5.2. Financial Performance

10.5.3. Product/Service Offerings

10.5.4. Strategies & recent developments

10.5.5. SWOT Analysis

10.6. Novartis

10.6.1. Business Overview

10.6.2. Financial Performance

10.6.3. Product/Service Offerings

10.6.4. Strategies & recent developments

10.6.5. SWOT Analysis

10.7. GSK (GlaxoSmithKline)

10.7.1. Business Overview

10.7.2. Financial Performance

10.7.3. Product/Service Offerings

10.7.4. Strategies & recent developments

10.7.5. SWOT Analysis

10.8. Sanofi

10.8.1. Business Overview

10.8.2. Financial Performance

10.8.3. Product/Service Offerings

10.8.4. Strategies & recent developments

10.8.5. SWOT Analysis

10.9. AstraZeneca

10.9.1. Business Overview

10.9.2. Financial Performance

10.9.3. Product/Service Offerings

10.9.4. Strategies & recent developments

10.9.5. SWOT Analysis

10.10. Dendreon

10.10.1. Business Overview

10.10.2. Financial Performance

10.10.3. Product/Service Offerings

10.10.4. Strategies & recent developments

10.10.5. SWOT Analysis

10.11. Celgene

10.11.1. Business Overview

10.11.2. Financial Performance

10.11.3. Product/Service Offerings

10.11.4. Strategies & recent developments

10.11.5. SWOT Analysis

10.12. Inovio Pharmaceuticals

10.12.1. Business Overview

10.12.2. Financial Performance

10.12.3. Product/Service Offerings

10.12.4. Strategies & recent developments

10.12.5. SWOT Analysis

10.13. Eli Lilly

10.13.1. Business Overview

10.13.2. Financial Performance

10.13.3. Product/Service Offerings

10.13.4. Strategies & recent developments

10.13.5. SWOT Analysis

10.14. Transgene

10.14.1. Business Overview

10.14.2. Financial Performance

10.14.3. Product/Service Offerings

10.14.4. Strategies & recent developments

10.14.5. SWOT Analysis

10.15. Sorrento Therapeutics

10.15.1. Business Overview

10.15.2. Financial Performance

10.15.3. Product/Service Offerings

10.15.4. Strategies & recent developments

10.15.5. SWOT Analysis